Related references
Note: Only part of the references are listed.Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F. Wang et al.
ANNALS OF ONCOLOGY (2019)
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku et al.
ANNALS OF ONCOLOGY (2019)
Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
Hongchuan Liu et al.
MABS (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase II pilot trial of nivolumab (N) plus albumin bound paclitaxel (AP) plus paricalcitol (P) plus cisplatin (C) plus gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
Erkut Hasan Borazanci et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Canadian Cancer Trials Group PA. 7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Daniel John Renouf et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemotherapy and radiotherapy for advanced pancreatic cancer
Venessa Chin et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
Jun Gong et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials
Dickran Kazandjian et al.
SEMINARS IN ONCOLOGY (2017)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Glen J. Weiss et al.
BRITISH JOURNAL OF CANCER (2017)
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M. Aglietta et al.
ANNALS OF ONCOLOGY (2014)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Share Paper
